In this issue:
Telaprevir resistance profile across HCV genotypes
HBV therapeutic vaccine disappoints
Long-term therapy for HBeAg+ patients
PUFA supplementation benefits HCV?
Improving the infant HBV immunisation programme
Please login below to download this issue (PDF)